Chemotherapy News and Research

Latest Chemotherapy News and Research

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

2 Jun 2010

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced that it has signed an agreement to raise over $5 million by selling 2 million shares of equity to Crisnic Fund, S.A. based on a 15% discount from the volume weighted average price on the date the SEC declares the registration effective, as detailed in the 8-K being filed today.

2 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Predictive biomarker for patients with NSCLC

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.

2 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer.

2 Jun 2010

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

US Oncology, Inc., the nation's leading integrated oncology company, today announced its new iKnowMed™ Technology Platform to support community oncologists nationwide. This new platform enhances cancer care quality and practice efficiency through integrated, oncology-specific technologies that enable community oncologists to solve challenges in the areas of care delivery, drug management, and revenue cycle management.

2 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Health Robotics South East Asia opens two outsourcing centers in Kuala Lumpur and Bangkok

Health Robotics today announced that its joint venture Health Robotics South East Asia Ltd. scored two strategic wins by reaching agreements on two separate government-sponsored projects to deliver CytoCare-made accurate and sterile oncology patient doses in Kuala Lumpur and Bangkok, respectively.

31 May 2010

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

Advances in cancer care help people diagnosed with cancer survive the disease

Ed Gardella, a police officer for 31 years, thought he was pretty tough. But then the 70-year old Worcester, Mass. resident was diagnosed with esophageal cancer. "You never forget that moment, where you were that moment you were told you have cancer," said Gardella. "I never thought I was a particularly brave man, nor did I think I was a coward. I was a police officer, a chief of police, but this disease brings everyone to their knees — no one is tougher than cancer."

29 May 2010

Patients with stage IIIA NSCLC who receive lobectomy have increased overall survival: Research

There's debate about the best treatment approach for patients with certain stages of non-small cell lung cancer, which accounts for about 80 percent of all lung cancers. Patients with early stages of NSCLC are typically treated with surgery, but those with stage IIIA present more of a challenge because they are such a diverse group.

29 May 2010

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.

29 May 2010

2010 Quality Index Reports on Ontario's Cancer System

Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.

28 May 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Light therapy may be alternative treatment for prostate cancer

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Predictive biomarker for patients with NSCLC

TQ can suppress growth of aggressive PCa cell lines: Researchers

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

FDA grants priority review status to Eisai's eribulin NDA

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Health Robotics South East Asia opens two outsourcing centers in Kuala Lumpur and Bangkok

Major response to preoperative therapy increases survival in pancreatic cancer patients

Advances in cancer care help people diagnosed with cancer survive the disease

Patients with stage IIIA NSCLC who receive lobectomy have increased overall survival: Research

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

2010 Quality Index Reports on Ontario's Cancer System

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in